These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38483020)

  • 21. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia.
    Cui L; Shu C; Liu Z; Tong W; Cui M; Wei C; Tang JJ; Liu X; Hu J; Jiang J; He J; Zhang DY; Ye F; Li Y
    Pregnancy Hypertens; 2018 Jul; 13():127-132. PubMed ID: 30177039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
    Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL
    Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
    Birdir C; Droste L; Fox L; Frank M; Fryze J; Enekwe A; Köninger A; Kimmig R; Schmidt B; Gellhaus A
    Pregnancy Hypertens; 2018 Apr; 12():124-128. PubMed ID: 29674192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes.
    Chang YS; Chen CN; Jeng SF; Su YN; Chen CY; Chou HC; Tsao PN; Hsieh WS
    Pediatr Neonatol; 2017 Dec; 58(6):529-533. PubMed ID: 28571908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
    Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
    Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.
    Villalaín C; Herraiz I; Valle L; Mendoza M; Delgado JL; Vázquez-Fernández M; Martínez-Uriarte J; Melchor Í; Caamiña S; Fernández-Oliva A; Villar OP; Galindo A
    J Am Heart Assoc; 2020 Apr; 9(7):e015548. PubMed ID: 32248765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
    Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV
    Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
    Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
    Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
    Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.